LIXTE BIOTECHNOLOGY HOLDINGS, INC.
NMADNext catalyst
LB-100
Ovarian Clear Cell Carcinoma
Get an email about NMAD's next catalysts
Track LIXTE BIOTECHNOLOGY HOLDINGS (NMAD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
NMAD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
LB-100 Phase 2 Est. Readout
Estimated primary completion for LB-100 trial (NCT06065462) in Ovarian Clear Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LB-100 | Phase 2 | Ovarian Clear Cell Carcinoma | - | - |
Frequently asked questions
What is in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (NMAD) pipeline across Phase 2. Its lead program is LB-100 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s next FDA catalyst?→
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s (NMAD) next tracked catalyst is a Phase 2 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NMAD biotech catalysts?→
Add NMAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.